



Divi's Laboratories Limited

March 22, 2017

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

Sub: Update on Import Alert issued by US-FDA on products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh

Further to our earlier communication dated 21st March, 2017 to the Stock Exchanges, we wish to update that the Import Alert by US-FDA for the products manufactured at the company's Unit-II at Visakhapatnam was issued under two clauses 66-40 & 99-32 of the FDA regulations.

As mentioned earlier, the Agency has exempted the following products from the Import Alert:

1. Levetiracetam
2. Gabapentin
3. Lamotrigine
4. Capecitabine
5. Naproxen sodium
6. Raltegravir potassium
7. Atovaquone
8. Chloropurine
9. BOC core succinate
10. 2,4-wing active ester

The company has already initiated necessary measures to address the concerns raised by the US-FDA and is making all efforts to fully meet the compliance requirements.

This is for your information and records.

Thanking you,

Yours faithfully

For **Divi's Laboratories Limited**


P.V. Lakshmi Rajani
Company Secretary



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com